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 Abstract
Introduction: Podoplanin is a transmembrane glycoprotein expressed in endothelial lymphatic cells. It was proven 
to be a predictive marker in a variety of cancers e.g. mesothelioma and head and neck squamous-cell carcinoma. 
Ovarian clear cell carcinoma (OCCC) is a rare and unique histopathologic subtype of epithelial ovarian cancer 
(EOC). The molecular basis of that phenomenon remains unknown.
Objectives: The aim of our study was to assess podoplanin expression on the protein level in OCCC. 
Material and Methods: Immunohistochemistry was performed on paraffin-embedded tissues from 19 patients 
with diagnosed OCCC. 
Results: Podoplanin expression was present (moderate or strong) in 52% of OCCC cases (10/19). Nine of eleven 
(81,2%) postmenopausal and one of eight (12,5%) premenopausal women were podoplanin positive. No differences 
in podoplanin expression were found in relation to clinical features of the tumor.
Conclusion: The incidence of podoplanin expression is higher in ovarian clear cell adenocarcinoma in 
postmenopausal patients. 
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Introduction
Podoplanin	 is	 a	 38	 kDa	 transmembrane	 glycoprotein,	
specifically	expressed	in	lymphatic	endothelial	cells	and	for	that	
reason	it	has	been	recognized	as	a	marker	for	lymphangiogenesis	
[1,	2].	The	 role	of	podoplanin	 in	 the	process	of	metastasis	has	
not	been	conclusively	determined.	Wicky	et	al.,	in	their	tests	in 
vitro and in vivo	proved	that	increased	expression	of	podoplanin	
leads	to	the	decrease	in	adhesion	and	stimulation	of	pathologic	
cell	migration	of	pectoral	gland	 tumor,	even	 in	 the	presence	of	
E-cadherin	 [3].	 Podoplanin	 possesses	 a	 platelet	 aggregation-
stimulating	(PLAG) domain	which	takes	part	in	blood	platelets	
activation	 and	 aggregation.	 Kunita	 et	 al.,	 in	 their	 research	 on	
animal	 models	 revealed	 that	 it	 visibly	 increases	 the	 ability	 of	
cancer	cells	 in	 the	circulating	blood	 to	metastasize.	The	ability	
has	been	significantly	compromised	after	introducing	mutations	
in	the	DNA	coding	the	PLAG	domain	[4].	Therefore,	podoplanin	
has	been	claimed	to	play	 the	role	of	a	certain	‘intensifier’,	and	
in	 some	 cases	 a	 modulator,	 of	 tumor	 progression	 [1].	 Ozaki	
et	 al.,	 claim	 that	 podoplanin	 may	 induce	 platelet	 aggregation	
also	 by	 interacting	 with	 its	 CLEC-2	 receptor	 (C-type	 lectin-
like	 receptor	2)	 [5].	One	of	 the	mechanisms	which	explain	 the	
phenomenon	of	cancer	cells	hiding	from	the	immune	system	may	
be	the	expression	of	podoplanin	which,	binding	with	the	CLEC-2	
receptor,	activates	blood	platelets	and	creates	a	thrombus	around	
the	tumor	[6].	
Clear	cell	carcinoma	accounts	 for	under	5%	of	all	ovarian	
tumors	[7].	Partial	response	to	therapy	is	the	most	characteristic	
feature	which	distinguishes	clear	cell	carcinoma	from	the	rest	of	
ovarian	tumors	[8,	9].	Literature	offers	the	reports	by	Oe	et	al.,	
who	assessed	the	expression	of	podoplanin	in	clear	cell	carcinoma	
[10]	 and	 found	 it	 to	 be	 significantly	 increased	 in	 OCCC,	 in	
comparison	with	other	histologic	types	of	ovarian	cancer.
The	aim	of	our	work	was	to	examine	immunohistochemical	
expression	of	podoplanin	in	ovarian	clear	cell	carcinoma.
Material and methods
19	patients	with	 clear	 cell	 carcinoma,	who	had	undergone	
surgery	at	I	Clinic	of	Oncological	Gynecology	and	Gynecology,	
Medical	 University	 of	 Lublin,	 were	 included	 into	 the	 study.	
The	study	has	been	approved	by	Bioethics	Committee,	Medical	
University	of	Lublin.	The	tests	were	performed	by	using	tissue	
microarray	 technique	 (TMA).	 Cylindrical	 tissue	 array	 blocks	
were	cut	out	of	paraffin-embedded	tissue	block	and	immersed	in	
the	recipient	blocks,	especially	designed	for	 the	purpose	of	 the	
study,	with	the	use	of	the	TMA	Olympus	device.	Representative	
cancerous	 tissue	 specimens,	2mm	 in	diameter,	were	cut	on	 the	
basis	of	hematoxylin	and	eosin	staining.	 Immunohistochemical	
staining	 was	 performed	 according	 to	 the	 procedure	 published	
by	Lesiak	et	al.	[11].	The	expression	of	podoplanin	with	the	use	
of	 rabbit	 polyclonal	 antibody	 at	 1:100	dilution	 (ABCAM)	was	
analyzed.	Visualization	was	carried	out	with	the	use	of	peroxidase	
–	tetrachloride	3,3-	Diaminobenzidine	(DAB).	
The	intensity	of	the	reaction	was	measured	on	a	scale	from	
0–3	(0	–	lack,	1	–	weak,	2	–	moderate,	3	–	strong).	0	and	1	were	
considered	‘negative’,	2	and	3	‘positive’.
Statistical analysis
The	results	were	statistically	analyzed	with	SPSS	version	14	
software,	 the	p	values	were	calculated	with	Fisher’s	exact	 test.	
p<0.05	was	considered	statistically	significant.	
Results
The	 study	 group	 included	 19	 women,	 8	 (42.2%)	 pre-
menopausal	 and	 11	 (57.8%)	 post-menopausal,	 diagnosed	
with	 clear	 cell	 ovarian	 carcinoma.	9	patients	were	FIGO	stage	
I	 (47.3%)	 and	10	were	FIGO	 stage	 II	 (52.6%).	 7	 tumors	were	
classified	as	G1	(36.8%)	and	12	as	G2	(63.2%).	The	results	are	
presented	in	table	I.
 Streszczenie
Wstęp: Podoplanina jest przezbłonową glikoproteiną występującą w komórkach śródbłonka naczyń 
limfatycznych. Swoje zastosowanie jako marker predykcyjny znalazła w diagnostyce międzybłoniaka czy też 
w raku głowy i szyi. Jasnokomórkowy rak jajnika (OCCC) jest rzadko występującym i odmiennym histopatologicznym 
podtypem nabłonkowego raka jajnika. Molekularne podłoże tego zjawiska nadal nie jest znane. 
Cel: Celem badań była ocena ekspresji podoplaniny na poziomie białka w jasnokomórkowym raku jajnika.
Materiał i metody: Ekspresję podoplaniny oceniono metodą immunohistochemiczną z zastosowaniem techniki 
macierzy tkankowych (TMA) u 19 pacjentek z OCCC.
Wyniki: Ekspresja podoplaniny była obecna (średnia lub wysoka) w 52% przypadków OCCC (10/19). Jej ekspresję 
wykazano u jednej spośród ośmiu pacjentek przed menopauzą (12,5%) i u 9 spośród 11 (81,2%) po menopauzie. 
Nie wykryto różnic w ekspresji podoplaniny w odniesieniu do cech klinicznych nowotworu. 
Wnioski: Częsta ekspresja podoplaniny jest charakterystyczna dla kobiet po menopauzie ze zdiagnozowanym 
rakiem jasnokomórkowym jajnika.  
 Słowa kluczowe: rak jasnokomórkowy / nabłonkowy rak jajnika / TMA / 
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Podoplanin expression 
Out	 of	 the	 19	 analyzed	 cases	 of	 clear	 cell	 carcinoma,	
moderate	 or	 strong	 podoplanin	 expression	was	 observed	 in	 10	
patients,	what	accounted	for	52%.	(Photo	1).	
It	was	weak	 in	 3	 cases	 (16%).	Membrane	 expression	was	
found	in	4	(31%)	and	cytoplasmic-membrane	in	9	cases	(69%).	
(Table	II).	No	differences	in	podoplanin	expression	in	different	
stages	 of	 advancement	 and	maturity	 of	 the	 tumor	were	 found.	
(Table	I).	
There	 were	 differences,	 however,	 in	 the	 expression	 of	
podoplanin	 with	 regard	 to	 menopausal	 status.	 Podoplanin	
expression	was	more	often	observed	(p=0.005)	 in	 the	group	of	
post-menopausal	(81.8%)	than	pre-menopausal	patients	(12.5%).	
(Figure	1).
Discussion
Presence	of	podoplanin	expression	was	found	in	a	significant	
number	of	cases	(52%)	of	ovarian	clear	cell	carcinoma.	Due	to	
the	rare	incidence	(<5%	of	all	EOC)	of	such	malignancy,	when	
comparing	 to	 other	 histologic	 subtypes,	 the	 study	 group	 was	
limited	in	number	(19	cases).	Regardless	of	that	fact,	the	obtained	
results	indicate	that	podoplanin	may	in	fact	play	a	significant	role	
in	the	lymphangiogenesis	of	clear	cell	ovarian	carcinoma.	Oe	et	
al.,	have	drawn	similar	conclusions	after	having	conducted	their	
study	 in	 a	 slightly	 larger	 group	 of	 patients	 (22	 cases	 –	 54.5%	
of	 the	 OCCC	 women	 demonstrated	 podoplanin	 expression).	
So	 far	 their	 findings	 have	 been	 the	 only	 report	 on	 the	 role	 of	
podoplanin	in	clear	cell	ovarian	carcinoma.	In	their	research	they	
noted	statistically	significantly	higher	podoplanin	expression	in	
Table I. Podoplanin expression with reference to clinical tumor features. 
Table II. Cell localization of podoplanin in patients with OCCC. 
 
Figure 1. Podoplanin expression with reference to patient age (%). 
 
 
Photo 1. High podoplanin expression within the cytoplasm and cell membrane in 
clear cell ovarian carcinoma (Dako EnVisionTM+/HRP; magnified 5x). 
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OCCC	when	compared	to	other	histological	subtypes	of	ovarian	
cancer.	 It	 correlated	with	 tumor	malignancy	and	poor	 response	
to	 therapy.	 Therefore,	 they	 claim	 the	 protein	 to	 be	 a	 marker	
differentiating	clear	cell	carcinoma	from	other	epithelial	ovarian	
cancers	 [10].	 The	 number	 of	 cases	 of	 OCCC	 with	 positive	
podoplanin	 expression	 confirmed	 by	 our	 study	 enables	 the	
authors	to	agree	with	the	conclusions	of	Oe	et	al.	It	is	necessary	
to	monitor	the	results	of	the	treatment	of	patients	with	OCCC	in	
order	to	determine	whether	that	carcinoma	occurs	in	two	possible	
groups	(podoplanin+	and	podoplanin-)	of	different	courses	of	the	
disease.	Bearing	in	mind	the	mechanisms	of	podoplanin	activity,	
its	 increased	 expression	 in	OCCC	might	 explain	 that	 fact	 that	
patients	with	clear	cell	carcinoma	are	more	prone	to	thrombosis	
than	patients	diagnosed	with	other	types	of	ovarian	cancer	[12].		
It	has	not	been	conclusively	resolved	whether	one	or	many	
mechanisms	 of	 podoplanin	 have	 the	 pathogenic	 influence	 on	
OCCC,	 at	 what	 stage	 of	 OCCC	 carcinogenesis	 the	 role	 of	
podoplanin	is	the	key	one,	whether	it	is	the	reason	or	the	cause	
of	 the	molecular	cancerous	processes	undergoing	within	a	cell.	
What	has	been	known	 is	 that	high	expression	of	podoplanin	 is	
induced	 during	 cell	 transformation	 dependant	 on	 the	 tyrosine	
kinase	Src.	Shen	et	al.,	concluded	on	the	basis	of	their	in vitro	tests	
that	 increased	expression	of	podoplanin	was,	 to	a	 large	degree,	
responsible	for	higher	migration	and	invasiveness	of	transformed	
cells	[13].	It	is	yet	another	proof	that	might	explain	the	different	
and	 aggressive	phenotype	of	OCCC,	particularly	 in	 cases	with	
increased	expression	of	podoplanin.
Suzuki-Inoue	et	al.,	demonstrated	in	tests	on	mice	that	using	
antibodies	 to	 block	 podoplanin	 protects	 from	 tumor	metastasis	
[6].	Other	authors	proved	that	transfection	and	ectopic	expression	
of	 CD9	 inhibited	 platelets	 aggregation,	 induced	 by	 Aggrus	
factor,	 and	 high	 expression	 of	 podoplanin	 in	 lung	 tumor.	As	 a	
result,	suppression	of	metastases	occurred	[14].	A	similar	effect	
was	 reported	by	Cortez	et	al.,	who	 lowered	high	expression	of	
podoplanin	 by	 inducing	 the	 expression	 of	 two	 microRNAs	
(miR-29b	and	miR-125A)	in	glioblastoma	and	suppressed	tumor	
invasion	[15].	
Taking	into	account	the	increased	expression	of	podoplanin	
observed	 by	 the	 authors	 of	 the	 present	 work	 and	 by	 Oe	 [10],	
the	abovementioned	mechanisms	might	be	used	in	treatment	of	
patients	diagnosed	with	clear	cell	ovarian	carcinoma.	Increased	
expression	of	podoplanin	might	 also	be	a	 significant	 factor	 for	
allowing	a	more	effective	differentiation	of	OCCC	in	the	highly	
heterogeneous	group	of	epithelial	ovarian	tumors.
In	 our	 study	 podoplanin	 expression	 was	 not	 statistically	
significant	with	regard	to	clinical	features	(FIGO,	tumor	maturity)	
(p>0.05).	 Its	 expression,	 however,	was	more	 characteristic	 (p=	
0,005)	in	case	of		post-menopausal	women	when	compared	to	pre-
menopausal	ones,	what	might	explain	more	aggressive	progression	
of	the	tumor	and	worse	prognosis	for	post-menopausal	women.	
These	findings	are	confirmed	by	tests	in	epithelial	ovarian	cancer	
group.	 The	 course	 of	 the	 disease,	 prognosis	 and	 response	 to	
therapy	were	significantly	better	in	the	group	of	pre-menopausal	
patients	[16,	17].	
In	 our	 work	 we	 have	 noticed	 almost	 69%	 cases	 of	 cyto-
plasmic-membrane	podoplanin	cell	localization.	Physiologically	
podoplanin	is	located	in	cell	membrane.	Its	accumulation	in	the	
cytoplasm	may	lead	to	other,	so	far	undiscovered,	anomalies	on	
the	 molecular	 level,	 for	 example	 signal	 transduction	 pathway.	
Clinical	 application	 of	 podoplanin	 as	 a	 marker	 might	 be	
broadened	if	the	influence	of	its	cell	localization	on	the	function	
was	explained.
Due	to	the	fact	that	clear-cell	ovarian	carcinoma	is	relatively	
rare	and	heterogeneous	in	nature	(papillary,	tubulocystic,	solid),	
selecting	 statistically	 representative	groups	of	 patients	 presents	
a	 considerable	 challenge.	 Therefore,	 the	 results	 of	 the	 authors	
of	 this	 article	 are	 preliminary	 and	 aim	 at	 presenting	 a	 certain	
tendency	 and	 at	 attracting	 attention	 to	 the	 possibility	 of	 using	
podoplanin	in	clinical	clear	cell	cancer	diagnosis.
Conclusions
Increased	 expression	of	 podoplanin	 is	 typical	 of	 clear	 cell	
ovarian	 cancer,	 especially	 for	 post-menopausal	 women	 with	
OCCC.
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